Dashboard
1
The company has declared Positive results for the last 3 consecutive quarters
- NET PROFIT(9M) At CNY 401.27 MM has Grown at 89.31%
- RAW MATERIAL COST(Y) Fallen by -4.8% (YoY)
- CASH AND EQV(HY) Highest at CNY 12,265.47 MM
2
With ROE of 6.14%, it has a fair valuation with a 1.74 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 11,491 Million (Large Cap)
28.00
NA
6.66%
-0.43
5.95%
1.00
Revenue and Profits:
Net Sales:
1,869 Million
(Quarterly Results - Mar 2026)
Net Profit:
403 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-19.49%
0%
-19.49%
6 Months
-20.54%
0%
-20.54%
1 Year
-16.51%
0%
-16.51%
2 Years
-36.91%
0%
-36.91%
3 Years
-58.4%
0%
-58.4%
4 Years
-48.43%
0%
-48.43%
5 Years
-73.9%
0%
-73.9%
By-health Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.52%
EBIT Growth (5y)
66.71%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.58
Tax Ratio
29.36%
Dividend Payout Ratio
96.38%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
21.48%
ROE (avg)
14.00%
Valuation key factors
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
1.74
EV to EBIT
17.44
EV to EBITDA
13.99
EV to Capital Employed
2.24
EV to Sales
2.51
PEG Ratio
2.40
Dividend Yield
3.11%
ROCE (Latest)
12.82%
ROE (Latest)
6.14%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Bearish
Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Jun 2017
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.02%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
1,868.80
1,791.70
4.30%
Operating Profit (PBDIT) excl Other Income
442.50
603.40
-26.67%
Interest
2.60
4.50
-42.22%
Exceptional Items
20.30
13.20
53.79%
Consolidate Net Profit
403.10
466.60
-13.61%
Operating Profit Margin (Excl OI)
236.80%
295.30%
-5.85%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 4.30% vs -31.99% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -13.61% vs -35.10% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
6,218.40
6,805.50
-8.63%
Operating Profit (PBDIT) excl Other Income
1,178.80
998.80
18.02%
Interest
15.80
13.80
14.49%
Exceptional Items
27.70
28.00
-1.07%
Consolidate Net Profit
816.60
647.90
26.04%
Operating Profit Margin (Excl OI)
142.90%
109.20%
3.37%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -8.63% vs -26.93% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 26.04% vs -63.58% in Dec 2024
About By-health Co., Ltd. 
By-health Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






